24 November 2022 - Based on POTENT study results.
Taiho Pharmaceutical announced today that the Japanese Ministry of Health, Labour and Welfare has approved an additional indication of post-operative adjuvant chemotherapy for hormone receptor positive and HER2 negative breast cancer at high risk of recurrence for its oral anti-cancer agent TS-1 combination capsules T20/T25, TS-1 combination granules T20/T25, and TS-1 combination OD tablets T20/T25 (tegafur with gimeracil and oteracil potassium).